TY  - JOUR
A1  - Baur, Johannes
A1  - Schedelbeck, Ulla
A1  - Pulzer, Alina
A1  - Bluemel, Christina
A1  - Wild, Vanessa
A1  - Fassnacht, Martin
A1  - Steger, U.
T1  - A case report of a solitary pancreatic metastasis of an adrenocortical carcinoma
JF  - BMC Surgery
N2  - Background
Solitary metastases to the pancreas are rare. Therefore the value of resection in curative intention remains unclear. In the literature there are several promising reports about resection of solitary metastasis to the pancreas mainly of renal origin.

Case presentation
Here we report for the first time on the surgical therapy of a 1.5 cm solitary pancreatic metastasis of an adrenocortical carcinoma. The metastasis occurred almost 6 years after resection of the primary tumor. A partial pancreatoduodenectomy was performed and postoperatively adjuvant mitotane treatment was initiated. During the follow-up of 3 years after surgery no evidence of tumor recurrence occurred.

Conclusion
Resection of pancreatic tumors should be considered, even if the mass is suspicious for metastatic disease including recurrence of adrenocortical cancer.
KW  - surgical treatment
KW  - adrenocortical
KW  - carcinoma metastases to pancreas
Y1  - 2015
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-126130
VL  - 15
IS  - 93
ER  - 
TY  - JOUR
A1  - Kunzmann, Volker
A1  - Herrmann, Ken
A1  - Bluemel, Christina
A1  - Kapp, Markus
A1  - Hartlapp, Ingo
A1  - Steger, Ulrich
T1  - Intensified neoadjuvant chemotherapy with nab-paclitaxel plus gemcitabine followed by FOLFIRINOX in a patient with locally advanced unresectable pancreatic cancer
JF  - Case Reports in Oncology
N2  - The prognosis of patients with locally advanced pancreatic cancer can be improved if secondary complete (R0) resection is possible. In patients initially staged as unresectable this may be achieved with neoadjuvant treatment which is usually chemoradiotherapy based. We report the case of a 46-year-old patient with an unresectable, locally advanced pancreatic cancer (pT4 Nx cM0 G2) who was treated with a sequential neoadjuvant chemotherapy regimen consisting of 2 cycles of nab-paclitaxel plus gemcitabine followed by 4 cycles of FOLFIRINOX. Neoadjuvant chemotherapy resulted in secondary resectability (R0 resection). After 2 cycles of nab-paclitaxel plus gemcitabine, the patient already had a complete metabolic remission as measured by integrated fludeoxyglucose ((18)F) positron emission tomography and computerized tomography. After a follow-up of 18 months the patient is alive without progression of disease. We propose to assess the clinical benefit of sequencing the combinations nab-paclitaxel plus gemcitabine and FOLFIRINOX as neoadjuvant therapy for patients with locally advanced and initially unresectable pancreatic cancer in a controlled clinical trial.
KW  - nab-paclitaxel
KW  - neoadjuvant chemotherapy
KW  - oxaliplatin
KW  - pancreatic cancer
KW  - locally advanced disease
KW  - irinotecan
KW  - gemcitabine
KW  - folinic acid
KW  - 5-Fluorouracil
Y1  - 2014
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-120189
SN  - 1662-6575
VL  - 7
IS  - 3
ER  -